Santiago Reyes
Pediatric Pulmonology · Oklahoma City, OKNPI 1497770911
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.
Across 242 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$592
- AstraZeneca$570
- Sanofi$486
- Xeris Pharmaceuticals, Inc.$358
- Regeneron Healthcare Solutions, Inc.$298
- Advanced Respiratory, Inc$289
- plus $2K from 30 others
Across 51 payments — averaging $6432.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$286K
- Teva Pharmaceuticals USA, Inc.$24K
- GSK$9K
- AstraZeneca$7K
- Janssen Research & Development, LLC$500
- Shionogi Inc$500
What the payments were for
- Food & beverage$4,74299%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 26 | $592 |
| AstraZeneca | 33 | $570 |
| Sanofi | 21 | $486 |
| Xeris Pharmaceuticals, Inc. | 17 | $358 |
| Regeneron Healthcare Solutions, Inc. | 12 | $298 |
| Advanced Respiratory, Inc | 18 | $289 |
| Philips North America LLC | 11 | $206 |
| Baxter Healthcare | 9 | $190 |
| GSK | 9 | $160 |
| Amgen | 8 | $156 |
| Aimmune Therapeutics, Inc. | 7 | $129 |
| Gilead | 7 | $109 |
| Neurocrine Biosciences, Inc. | 4 | $95 |
| Arbor Pharmaceuticals, Inc. | 4 | $95 |
| Dexcom, Inc. | 4 | $91 |
| Mannkind Corporation | 5 | $84 |
| Genentech USA, Inc. | 5 | $82 |
| Chiesi USA, Inc. | 4 | $78 |
| Nestle Healthcare Nutrition Inc. | 3 | $65 |
| Vertex | 3 | $63 |
| Sobi, Inc | 4 | $61 |
| AbbVie(2 entities) | 4 | $59 |
| Electromed, Inc. | 4 | $58 |
| Tolmar, Inc. | 3 | $56 |
| Lilly USA, LLC | 3 | $47 |
| Novartis | 3 | $44 |
| Eton Pharmaceuticals, Inc. | 1 | $38 |
| Vivus LLC | 2 | $34 |
| Resmed Corp | 1 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Abbott | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
How this compares
Too few pediatric pulmonology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 24 | $633,386 |
| CreonLipase/Protease/Amylase | 29 | $176,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $20,239 |
| Azithromycin | 17 | $597 |
| Omeprazole | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $63 | $633,38624 claims |
| AbbVieCreon | $59 | $176,70929 claims |
| GSKTrelegy Ellipta | $160 | $20,23931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric pulmonology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other pediatric pulmonology in Oklahoma City
- Nighat MehdiOklahoma City$2K
- Reeja DanielOklahoma City$145
- Richard de VuystOklahoma City$38
- Lee DroemerTulsa$7K
- Joseph WalterTulsa$7K
- Bucy ThomasBethany$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.